Studying antibody-drug conjugate targets in pediatric solid and brain tumors
Part of Brain & nervous system, Cancer clinical trials.
This study looks at how often certain targets (antigens) are present on the surface of cancer cells in children and young adults with solid tumors or brain tumors that have come back or not responded to treatment. The goal is to help design better treatments using antibody-drug conjugates (ADCs), which are drugs that specifically attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child were between 0 and 30 years old when first diagnosed with a solid tumor or brain tumor.
- The tumor has come back after treatment or did not respond to standard treatment.
- A stored tumor tissue sample (at least 15–30 slides) is available for testing.
- Life expectancy is at least 12 weeks (for the prospective part).
- For a separate part of the study, you or your child must have previously received an antibody-drug conjugate (ADC) treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
This trial studies how personalized (tailored) genetic testing can help guide care for children with cancer. It may help match treatment choices to each child’s genetic risk, and it includes optional return of germline (inherited) test results.
This trial tests a new type of immune cell therapy called CAR T cells that target a protein called B7-H3 found on many solid tumors. It is for children and young adults whose cancer has come back or stopped responding to standard treatments.
This study collects and studies tissue or bone marrow samples from certain childhood tumors. The goal is to learn what’s going on inside the cancer (using molecular testing) to better understand the disease and how it may respond to treatment.
This study looks at how young people with certain brain tumors respond to treatment. It aims to understand why some tumors resist therapy, which may help improve future treatments.
This trial tests a new immune therapy using your child's own specially trained white blood cells to fight brain tumors. The treatment is given directly into the fluid around the brain, and it is for children with specific types of brain cancer.
Hear when a new CNS Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.